Regulation 3 Sponsor of a clinical trial
United Kingdom
In these Regulations, subject to the following paragraphs, “sponsor” means, in relation to a clinical trial, the person who takes responsibility for the initiation, management and financing (or arranging the financing) of that trial.
If two or more persons take responsibility for the matters specified in paragraph (1) in relation to a clinical trial, those persons may—
take joint responsibility for carrying out the functions of the sponsor of that trial under these Regulations; or
allocate responsibility for carrying out the functions of the sponsor of that trial in accordance with paragraphs (4) to (10).
If two or more persons take joint responsibility in accordance with paragraph (2)(a)—
any reference to the sponsor in these Regulations shall, in relation to that trial, be construed as a reference to those persons; and
paragraphs (4) to (10) shall not apply.
The F3request for approval referred to in F4regulation 16 shall specify—
who, in accordance with paragraph (4), is responsible for carrying out the functions of the sponsor under Part 3;
who is to be responsible for carrying out the functions of the sponsor under Part 4 (good clinical practice and the conduct of clinical trials); and
who is to be responsible for carrying out the functions of the sponsor under Part 5 (pharmacovigilance).
After the clinical trial has been F5approved in accordance with regulation 18 F6or 18A, a different person may be specified as responsible for carrying out the functions of the sponsor under Part 3, 4 or 5 by making a F7modification of an important detail as defined in Part 3 to the terms of a clinical trial F8approval in accordance with F9regulation 22.
Where a person is responsible for carrying out the functions of the sponsor under Part 3 by virtue of paragraph (5), or is specified in accordance with paragraph (6) as responsible for those functions, any reference to the sponsor in—
that Part F10...,
F11... Schedule 3,
Schedule 5 F12..., and
Schedule 12,
shall, in relation to the trial, be construed as a reference to that person.
Where a person is specified in accordance with paragraph (5) or (6) as responsible for carrying out the functions of the sponsor under Part 4, any reference to the sponsor in—
that Part, except regulation 28(1), or
Schedule 5, in so far as it relates to notices under regulation 31(1),
shall, in relation to the trial, be construed as a reference to that person.
Where a person is specified in accordance with paragraph (5) or (6) as responsible for carrying out the functions of the sponsor under Part 5, any reference to the sponsor in that Part shall, in relation to the trial, be construed as a reference to that person.
A person who is a sponsor of a clinical trial in accordance with this regulation must—
be established in F15the United Kingdom or a country that is included in the list referred to in paragraph (11A), or
have a legal representative who is so established.
A person who is a sponsor of a clinical trial in accordance with this regulation may delegate any or all of his functions under these Regulations to any person but any such arrangement shall not affect the responsibility of the sponsor.
The licensing authority must publish a list of countries where a sponsor of a clinical trial, or their legal representative, may be established for the purpose of paragraph (11).
In order to determine whether a country should be included in the list referred to in paragraph (11A), the licensing authority may, in particular, take into account—
the mechanisms that the country has in place to assist the licensing authority in contacting, or obtaining information in respect of, a sponsor or legal representative that is established there; and
the country's ability to assist the licensing authority in any action it may need to take in respect of a sponsor or legal representative that is established there.
The licensing authority must—
review the countries it has included in the list referred to in paragraph (11A) to determine if it is still satisfied that the country should remain on that list, and if it is not so satisfied, remove that country from the list; and
undertake such a review at least every three years beginning on the date on which that country is included in that list.
Annotations
Textual amendments
- F1
Words in reg. 3(4) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(2)(a)
- F2
Words in reg. 3(4) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(2)(b)
- F3
Words in reg. 3(5) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(2)(a)
- F4
Words in reg. 3(5) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(2)(b)
- F5
Word in reg. 3(6) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(3)(a)
- F6
Words in reg. 3(6) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(3)(b)
- F7
Words in reg. 3(6) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(3)(c)
- F8
Word in reg. 3(6) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(3)(d)
- F9
Words in reg. 3(6) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(3)(e)
- F10
Words in reg. 3(7)(a) omitted (28.4.2026) by virtue of The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(4)(a)
- F11
Words in reg. 3(7)(b) omitted (28.4.2026) by virtue of The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(4)(b)
- F12
Words in reg. 3(7)(c) omitted (28.4.2026) by virtue of The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(4)(c)
- F13
Words in reg. 3(10)(a) substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(5)(a)
- F14
Words in reg. 3(10)(c) omitted (28.4.2026) by virtue of The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 4(5)(b)
- F15
Words in reg. 3(11)(a) substituted (31.12.2020) by The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/744), regs. 1, 5(2); 2020 c. 1, Sch. 5 para. 1(1)
- F16
Reg. 3(12) inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 3(b)
- F17
Reg. 3(11A)-(11C) inserted (31.12.2020) by The Medicines for Human Use (Clinical Trials) (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/744), regs. 1, 5(3); 2020 c. 1, Sch. 5 para. 1(1)